INS and hematocrit: In terms of baseline medications, HT patients were more frequently treated with vitamin K antagonist (9.3% vs. 4.5%, P < 0.001), novel oral anticoagulants (5.6% vs. 2.7%, P < 0.001), and insulin (15.6% vs. 12.7%, P < 0.001).